Day One Biopharmaceuticals Inc (DAWN) Stock Price, Quote & News

Company Profile

Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 484 0899

Website: dayonebio.com

Address:

1800 Sierra Point Parkway, Suite 200, Brisbane, United States

TheGunnerAB Mar. 13 at 3:06 AM

$TGTX i owned $DAWN that was acquired last Friday. It was my biggest position by far. People who follow me knew about DAWN. It was sold at 10X 2026 revenues with their patent expiring in 2035. TGTX at this year 10X revenues is an MC of $10B with patent expiration in 2042.

7 · Reply

Stackdoe101 Mar. 12 at 9:51 PM

$DAWN We did it!! +101% 🙂✨️

0 · Reply

GeniusLoci Mar. 12 at 4:42 PM

$DAWN Let go of DAWN for a 212% short-term gain. Recycled the proceeds into $LEGN and $VSTM

1 · Reply

erevnon Mar. 11 at 3:06 PM

JP Morgan downgrades Day One Biopharmaceutical $DAWN from Overweight to Neutral and lowers the price target from $27 to https://marketsblock.com/stock-upgrades-and-downgrades/

1 · Reply

KingTrades09 Mar. 11 at 12:28 PM

@gpaisa were you in $DAWN Damnn they had a buyout couple days ago. I rememebr you posted somrthing about the chart last month or something

0 · Reply

SuperGreenToday Mar. 10 at 4:57 PM

$DAWN Share Price: $21.33 Contract Selected: Oct 16, 2026 $20 Calls Buy Zone: $0.98 – $1.21 Target Zone: $1.83 – $2.24 Potential Upside: 77% ROI Time to Expiration: 219 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Word0025 Mar. 10 at 3:32 PM

It is my belief that $DAWN is still bullish because buyers and sellers aren't budging from 21.30.

1 · Reply

Ms_P Mar. 10 at 1:31 PM

$DAWN We would likely would hear relatively soon if there was to be a bidding war. Will wait a few weeks before selling.

0 · Reply

F_Hansen Mar. 10 at 9:29 AM

$DAWN microcap style asymmetry, low attention plu

0 · Reply

jferrer2016 Mar. 10 at 12:56 AM

$DAWN when is this going to drop to $18

1 · Reply

Are DAWN and TALK Obtaining Fair Deals for their Shareholders?

TALK

Mar 6, 2026, 4:01 PM EST - 7 days ago

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN)

Mar 6, 2026, 1:39 PM EST - 7 days ago

Is there any upside left in DAWN stock as it soars 65%?

Mar 6, 2026, 10:04 AM EST - 7 days ago

Day One Shares Surge After $2.5B Servier Deal

Mar 6, 2026, 8:38 AM EST - 7 days ago

Servier to buy Day One Biopharmaceuticals for total equity value of $2.5 billion

Mar 6, 2026, 8:30 AM EST - 7 days ago

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio

Mar 5, 2026, 2:41 PM EST - 8 days ago

Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth

Feb 27, 2026, 3:29 PM EST - 14 days ago

Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead

Feb 25, 2026, 6:11 AM EST - 17 days ago

Day One Biopharmaceuticals, Inc. (DAWN) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 4:00 PM EST - 17 days ago

Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

Feb 10, 2026, 8:30 AM EST - 4 weeks ago

Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

Jan 13, 2026, 12:35 AM EST - 2 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 11, 2026, 5:00 PM EST - 2 months ago

Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance

Jan 6, 2026, 9:02 AM EST - 2 months ago

Day One Completes Acquisition of Mersana Therapeutics

Dec 18, 2025, 3:46 PM EST - 3 months ago

Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026 - I'm Bullish

Dec 16, 2025, 8:30 AM EST - 3 months ago

Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 24, 2025, 8:00 AM EST - 3 months ago

Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Nov 18, 2025, 8:30 AM EST - 4 months ago

Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 10:15 AM EST - 4 months ago

Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout

MRSN

Nov 13, 2025, 6:00 AM EST - 4 months ago

Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

Nov 10, 2025, 7:00 AM EST - 4 months ago

Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Nov 4, 2025, 8:36 PM EST - 4 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:00 PM EST - 4 months ago

Day One Reports Third Quarter 2025 Financial Results and Corporate Progress

Oct 21, 2025, 8:30 AM EDT - 5 months ago

Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025

Aug 7, 2025, 10:26 PM EDT - 7 months ago

Day One Biopharmaceuticals: Bear Case Priced In, But Bull Case Is Not (Rating Upgrade)

Aug 5, 2025, 9:19 PM EDT - 7 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:00 PM EDT - 7 months ago

Day One Reports Second Quarter 2025 Financial Results and Corporate Progress

Jul 22, 2025, 8:30 AM EDT - 8 months ago

Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025

Jun 10, 2025, 8:30 AM EDT - 9 months ago

Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

Jun 4, 2025, 8:59 PM EDT - 10 months ago

Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301

May 6, 2025, 10:12 PM EDT - 11 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:01 PM EDT - 11 months ago

Day One Reports First Quarter 2025 Financial Results and Corporate Progress

Apr 22, 2025, 8:30 AM EDT - 11 months ago

Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

Apr 10, 2025, 11:51 PM EDT - 1 year ago

Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity

Feb 26, 2025, 7:02 AM EST - 1 year ago

Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 4:05 PM EST - 1 year ago

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

Feb 11, 2025, 8:30 AM EST - 1 year ago

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

Jan 7, 2025, 11:31 AM EST - 1 year ago

Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)

Dec 25, 2024, 7:31 AM EST - 1 year ago

Day One Biopharmaceuticals: Sales Figures In The Crosshairs

Dec 17, 2024, 8:30 AM EST - 1 year ago

Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 20, 2024, 4:30 PM EST - 1 year ago

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

Nov 18, 2024, 8:30 AM EST - 1 year ago

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference

Oct 30, 2024, 10:57 PM EDT - 1 year ago

Day One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:01 PM EDT - 1 year ago

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

Oct 16, 2024, 8:30 AM EDT - 1 year ago

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Day One Announces Oversubscribed $175.0 Million Private Placement

TheGunnerAB Mar. 13 at 3:06 AM

7 · Reply

Stackdoe101 Mar. 12 at 9:51 PM

$DAWN We did it!! +101% 🙂✨️

0 · Reply

GeniusLoci Mar. 12 at 4:42 PM

$DAWN Let go of DAWN for a 212% short-term gain. Recycled the proceeds into $LEGN and $VSTM

1 · Reply

erevnon Mar. 11 at 3:06 PM

JP Morgan downgrades Day One Biopharmaceutical $DAWN from Overweight to Neutral and lowers the price target from $27 to https://marketsblock.com/stock-upgrades-and-downgrades/

1 · Reply

KingTrades09 Mar. 11 at 12:28 PM

@gpaisa were you in $DAWN Damnn they had a buyout couple days ago. I rememebr you posted somrthing about the chart last month or something

0 · Reply

SuperGreenToday Mar. 10 at 4:57 PM

0 · Reply

Word0025 Mar. 10 at 3:32 PM

It is my belief that $DAWN is still bullish because buyers and sellers aren't budging from 21.30.

1 · Reply

Ms_P Mar. 10 at 1:31 PM

$DAWN We would likely would hear relatively soon if there was to be a bidding war. Will wait a few weeks before selling.

0 · Reply

F_Hansen Mar. 10 at 9:29 AM

$DAWN microcap style asymmetry, low attention plu

0 · Reply

jferrer2016 Mar. 10 at 12:56 AM

$DAWN when is this going to drop to $18

1 · Reply

Word0025 Mar. 9 at 7:42 PM

$DAWN IS STILL STUCK!!! IT HIT A WALL AND IT AIN’T MOVING!!! THEY’VE BEEN RALLYING SINCE LAST FRIDAY!!!!

0 · Reply

GriZlyBeAr Mar. 9 at 7:40 PM

$DAWN $VNDA this is worth 40-50 but the only question is how corrupt is everyone behind the scenes. I have seen many other bios go for less than expected so really I could see this going for anywhere between 24-50.

1 · Reply

cb28 Mar. 9 at 7:28 PM

$DAWN $VNDA truthfully a low offer if that would be what we get, glp-1 addition would certainly sweeten the pie.

1 · Reply

GriZlyBeAr Mar. 9 at 7:19 PM

$DAWN $VNDA multiple suitors incoming! More than $18

0 · Reply

Rawbinhood Mar. 9 at 7:07 PM

$VNDA $DAWN BO incoming $18 per Share!!!

1 · Reply

RadioIsotope25 Mar. 9 at 4:39 PM

$DAWN RAD101 is batting 95% in finding cancerous tumors after stereotactic radiation (cyber knife) current high unmet medical need. 300,000 patients in america need this imaging agent. Current mri won’t show the cancer after cyber knife. Quoted as being the 3rd biggest potentially imaging drug in america behind Lantheus and Telix’s prostate drugs. How I got to 95% 10/10 in phase 2a and 11/12 in phase 2b… phase 2b slated to have data out after it finishing enrollment this month. Last time it traded up to $24 per share. At 60 million market cap this is a diamond in the rough. Like buying a Jordan rookie card for $5 $30 target by Jones. $RADX

0 · Reply

anachartanalyst Mar. 9 at 4:02 PM

$DAWN https://anachart.com/wp-content/uploads/ana_temp/1773072095_soc-img.jpg

0 · Reply

Word0025 Mar. 9 at 2:36 PM

$DAWN Still stuck on the ceiling barely moving!

0 · Reply

jferrer2016 Mar. 9 at 1:18 PM

$DAWN lets see

1 · Reply

ZacksResearch Mar. 9 at 1:10 PM

$DAWN just exploded **66% on a $2.5B buyout** — big pharma making a bold oncology bet 💥 Servier agreed to acquire Day One for **$21.50 per share**, adding the **brain tumor drug Ojemda** along with additional oncology pipeline assets to its portfolio. See what’s behind the deal 👉 https://www.zacks.com/stock/news/2880713/dawn-stock-jumps-66-on-25b-buyout-offer-from-servier?cid=sm-stocktwits-2-2880713-teaser-36501&ADID=SYND_STOCKTWITS_TWEET_2_2880713_TEASER_36501

1 · Reply

Word0025 Mar. 9 at 12:18 PM

$DAWN hit the ceiling y’all!

1 · Reply

Market Cap	2.20B
Revenue (ttm)	158.18M
Net Income (ttm)	-107.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-67.85%
Debt to Equity Ratio	0.00

Volume	5,101,500
Avg Vol	4,637,970
Day's Range	N/A - N/A
Shares Out	103.30M
Stochastic %K	99%
Beta	-1.25
Analysts	Sell
Price Target	$20.62